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ABSTRACT: Peptidomimetics containing (S)- or (R)-imidazolidin-2-one-4-
carboxylate (Imi) have been obtained by the expedient in-peptide cyclization
of (S)- or (R)-α,β-diaminopropionic acid (Dap) residues. These Imi scaﬀolds
behave as proline analogues characterized by a ﬂat structure and a trans-
restricted geometry of the preceding peptide bond and induce well-deﬁned
secondary structures in a biomimetic environment. While (S)-Imi peptides
adopted a γ′-turn conformation, (R)-Imi induced the contemporary formation
of a γ-turn and a rare 11-membered H-bonded structure in the 2→4 opposite
direction of the sequence, identiﬁed as a ε-turn. In order to exploit these Imi
scaﬀolds as general promoters of unusual secondary structures, proteinaceous
side chains have been introduced at the N1 position of the ﬁve-membered ring, potentially mimicking any residues. Finally, the
Imi rings have been equipped with unnatural side chains or with functionalized substituents, which can be utilized as linkers to
chemoselectively bind the Imi-peptides onto nanoparticles, biomaterials, or diagnostic probes.
■ INTRODUCTION
Heterocyclic-based peptidomimetics have been widely utilized
to increase metabolic and conformational stability of the parent
peptides.1 Amid them, N-heterocycles are prevalent in
biologically active peptides and are increasingly attractive
scaﬀolds in the development of new pharmaceuticals.2
Relevant examples include pseudo-prolines,3 Freidinger−
Veber lactams or analogues,4 and cyclic urea scaﬀolds.5
In particular, the latter have been utilized as structural
elements in peptidomimetic inhibitors of HIV protease and
HIV replication,6 antibacterial MurB inhibitors,7 dopamine D4
and CGRP receptor antagonists,8 angiotensin converting
enzyme (ACE) inhibitors,9 serine protease inhibitors,10 and
integrin inhibitors.11 In the literature, cyclic ureas are most
commonly constructed via treatment of 1,2-diamine precursors
with carbonyldiimidazole,6 or by intramolecular diamination of
alkenes,12 via rearrangement of Asn,9,13 via ring expansion of
aziridine derivatives,14 by cyclization of aza-propargylglycina-
mides,5b by alkylation of the urea nitrogen of semicarbazone
residues,15 by Pd-catalyzed urea carboamination reactions,16
and so on. Although a number of synthetic methods are
available, many are not feasible in peptide chemistry. Thus,
alternative strategies for the construction of cyclic ureas would
provide more facile access to a class of peptidomimetics that
are not readily available.
In this context, herein, we report the expedient synthesis of
peptidomimetics containing imidazolidin-2-one-4-carboxylate
(Imi) scaﬀolds by cyclization of sequences containing α,β-
diaminopropionic acid (Dap). The unexpected conformational
features of the Imi-peptides are also discussed with the aid of
NMR analysis and molecular dynamics simulations.
Furthermore, peptides containing Nβ-substituted Dap have
been obtained from β-iodoalanine by displacement with N-
nucleophiles. The cyclization of the substituted Dap residues
gave access to Imi-peptides carrying proteinogenic or unnatural
side chains at the position 1 or eventually providing useful
handles at which to undertake site-selective modiﬁcations of
the sequences.17 As a proof of concept, the allyl substituent at
the position 1 of the Imi ring was selectively derivatized by the
Heck reaction.
■ RESULTS AND DISCUSSION
Imi-Peptides Synthesis.Model peptides 2 containing (S)-
or (R)-Imi scaﬀolds have been obtained by the easy cyclization
of the corresponding sequences 1 containing Dap (Scheme 1
and Table 1). The preparation of the peptides 1a−c was
conducted by coupling in solution Boc-protected amino acids
to amino ester counterparts under MW irradiation18 using a
Received: November 29, 2018
Published: April 8, 2019
Scheme 1. In-Solution Preparation of Imi-Peptides 2 from
Dap-Peptides 1
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microwave oven speciﬁcally designed for organic synthesis,
with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
(EDC)·HCl and 1-hydroxybenzotriazole (HOBt) as activating
agents, in the presence of triethylamine (TEA). Several Dap-
protected variants are commercially available; herein, Dap was
introduced as Boc-Dap(Cbz)-OH. In any case, Dap can be
rapidly prepared following the literature19 and protected
thereafter with the appropriate group. Boc deprotection was
performed with 25% triﬂuoroacetic acid (TFA) in dichloro-
methane (DCM). The intermediates, obtained in quantitative
yield, were not puriﬁed, while the ﬁnal sequences 1a−c were
isolated in 80−85% yield by ﬂash chromatography over silica
gel (eluent 1:2 cyclohexane/EtOAc). Their identity was
conﬁrmed by ESI MS analysis, and purity was assessed to be
80−90% by RP HPLC.
After removal of the Nβ-Cbz group by catalytic hydro-
genation, the Dap-peptides were treated without further
puriﬁcations with N,N′-disuccinimidyl carbonate (DSC)3b,c
and N,N-diisopropylethylamine (DIPEA) in 3:1 DCM/DMF,
giving the Imi-peptides 2a−c in good yield (86−91%) after
isolation by semipreparative RP HPLC (Scheme 1, Table 1),
>90% pure as determined by analytical RP HPLC. The identity
of the compounds 2a−c (and of the Imi-peptides described in
the next sections) was conﬁrmed by exact mass, proton-
decoupled 13C NMR, and 1H NMR (the unambiguous
assignment of the resonances was done by 2D gCOSY).
Also, Imi-peptides were successfully obtained by solid-phase
peptide synthesis (SPPS) (Scheme 2). The tetrapeptides Boc-
Val-Ala-(S)/(R)-Dap(Cbz)-Phe-resin (1d, 1e) were prepared
onto a Phe-preloaded Wang resin using standard Fmoc-
protected amino acids and the dicyclohexylcarbodiimide
(DCC)/HOBt coupling agents under MW irradiation. Fmoc
was removed by treatment with piperidine/DMF. After
deprotection of the Cbz group by catalytic hydrogenation
with ammonium formate (4 equiv) in isopropanol/toluene,20
cyclization was done on resin with DSC and DIPEA (3 equiv
each) under recently reﬁned reaction conditions.21 Subse-
quently, the cleavage from the resin with reﬂuxing MeOH/
TEA (Scheme 2)22 gave the peptides 2d or 2e, isolated in a
very satisfactory yield and purity (84 and 86%, respectively,
calculated on the basis of the average resin load, Table 1) as
described above. These peptides were prepared as methyl
esters and with Boc at the N-terminus, for structural
comparison with the peptides 2b, c (see next paragraph).
Epimerization of Dap during peptide synthesis and
cyclization, in solution or in solid phase, was excluded on
the basis of the analysis of the reaction mixtures of 2a−c by
HPLC MS and NMR.
Conformational Analysis. X-ray crystallographic analysis
of 3-acyl-imidazolidine-2-one-4-carboxylates showed that these
heterocycles have a planar imidazolidine-2-one ring, and the
amide bond at the 3-position is restricted to the trans
geometry, coplanar with the ﬁve-membered ring.23 Theoretical
computations quantiﬁed that the diﬀerences in potential
energy between the cis- and trans-conformers were so large
that the unstable cis-conformer would have an extremely low
concentration.23 This is in contrast to proline, which shows a
puckered conformation of the pyrrolidine ring and is involved
in a trans/cis equilibrium about the preceding amide bond.24
Hence, it is expected that the introduction of Imi scaﬀolds into
a peptide sequence might impose alternative conformations
and unusual secondary structures. Previous investigations on
oligopeptides containing oxazolidin-2-one-4-carboxylates as
pseudo-prolines showed the ability of the heterocycles to
stabilize turns, foldamers,3c,d,25 or even to form hydrogels.26
In this perspective, the conformational bias exerted by the
Imi scaﬀold on the overall structure of model tetrapeptides was
analyzed by NMR experiments at 400 MHz in 8:2
[D6]DMSO/H2O, a solvent mixture recommended by several
authors as an excellent biomimetic medium, in which
intermolecular interactions are generally negligible for peptide
concentrations in the millimolar range.27 In any case, self-
association of the peptides was excluded based on the absence
of concentration eﬀects on the chemical shift of non-
exchangeable protons.25,28 As representative examples, we
analyzed the tetrapeptides 2b and 2c, which include (S)- or
(R)-conﬁgured Imi, respectively, at the position 2 of the
sequence, and peptides 2d and 2e having (S)- or (R)-Imi at the
position 3. All spectra showed a single set of sharp resonances,
suggestive of conformational homogeneity or of a fast
equilibrium between slightly diﬀerent conformers (Supporting
Information). gCOSY experiments were utilized for the
unambiguous assignment of the resonances.
In analogy to what was observed for peptides containing
oxazolidin-2-one-4-carboxylates, a nonconventional ImiC
O···H−C(α-1) intramolecular H-bond was expected (Figure
1).3c,d,25 Indeed, the 1H NMR analyses of all of the compounds
showed a signiﬁcantly downﬁeld position of the α-proton of
the residues preceding the Imi rings, consistent with the
deshielding eﬀect exerted by ImiCO for a trans
conformation of the amide bond between Ala1−Imi2 (Figure
1). For instance, in Boc-Ala-(S)-Imi-Phe-Val-OMe (2b), the
resonance of AlaHα appeared at about 5.2 ppm, while PheHα
and ValHα appeared at about 4.6 and 4.2 ppm.
Variable-temperature (VT) 1H NMR experiments have been
widely utilized as a tool for structure investigation in
polypeptides. Usually, for proteins or “rigid” peptides, the H-
Table 1. Synthesis of Model Imi-Peptides 2 by Cyclization
of the Corresponding Dap-Containing Peptides with DSC/
DIPEA
2 sequence
peptide
synthesis yield % purity %a
a Boc-Ala-(S)-Imi-Phe-OMe in-solution 86b 92
b Boc-Ala-(S)-Imi-Phe-Val-OMe in-solution 88b 93
c Boc-Ala-(R)-Imi-Phe-Val-OMe in-solution 91b 93
d Boc-Val-Ala-(S)-Imi-Phe-OMe SPPS 84c 95
e Boc-Val-Ala-(R)-Imi-Phe-OMe SPPS 86c 96
aDetermined by RP HPLC. bYield of the cyclization step, after
isolation by RP HPLC. cCalculated on the average resin load, after
isolation by RP HPLC.
Scheme 2. SPPS of Imi-Peptides 2d or 2e
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bonded amide-NH signals are characterized by modest
temperature gradients in absolute value, that is, |ΔδNH/Δt| ≤
2.5 ppb/K,29 while solvent-exposed NHs have larger negative
values. Unfortunately, for acyclic peptides, this “rule” has many
exceptions.30 Starting from these assumptions, we analyzed the
ΔδNH/Δt of 0.01 M 2b−e, in a 8:2 mixture of [D6]DMSO/
H2O (Table S1 and Figure 1). For Boc-Ala-(S)-Imi-Phe-Val-
OMe (2b), the comparatively much lower Δδ/Δt absolute
value of Phe3NH (−0.9 ppb/K) with respect to Ala1NH and
Val4NH (−3.7, and −4.5 ppb/K, respectively) indicatively
suggested that the former might be involved in a H-bond. On
the other hand, peptides 2c, d showed high |Δδ/Δt| values for
all amide-NHs. Unexpectedly, Ala2NH in Boc-Val-Ala-(R)-Imi-
Phe-OMe (2e) appeared to be signiﬁcantly less sensitive to
increasing temperature than Val1NH and Phe4NH (Δδ/Δt =
−2.4 vs −6.5 and −5.2 ppb/K, respectively), which might be
compatible with a preference for a conformation having
AlaNH involved in a H-bond.
The model compounds were analyzed by 2D-ROESY in 8:2
[D6]DMSO/H2O, using 0.01 M peptide concentration, and
the resulting cross-peaks were ranked by the intensity to infer
plausible interproton distances. Compared to the homochiral
Imi-peptides 2b and 2d, the heterochiral sequences 2c and 2e
showed several inter-residue proton−proton correlations
between nonconsecutive residues (Figure 1 and Supporting
Information).
The estimated distances were analyzed by simulated
annealing and restrained molecular dynamics simulations31
using the AMBER force ﬁeld32 in explicit water as a solvent. In
brief, random geometries of each peptide were obtained by
high-temperature unrestrained molecular dynamics simulation
in a box of standard TIP3P models of equilibrated water.33 For
each random structure, the interproton distances deduced by
ROESY were introduced as constraints. Neither H-bond
interactions nor torsion angle restraints were introduced,
while ω bonds were restricted at 180° because the absence of
Hαi − Hα(i + 1) cross-peaks excluded the occurrence of cis
peptide bonds.34 Then, the structures were subjected to high-
temperature restrained molecular dynamics with a scaled force
ﬁeld, followed by a simulation period with full restraints. After
slowly cooling the boxes, the geometries were minimized and
the backbones of the Imi-peptides were clustered by the rmsd
analysis.31 In all cases, this procedure gave one major cluster
comprising the majority of the structures (Figure S1). The
representative conformers with the lowest energy are reported
in Figure 2.
Among the four peptide models, the homochiral structures
2b and 2d showed comparatively more extended backbone
conformations, as expected on the basis of the negligible
number of inter-residue ROESY cross-peaks (Figure 1). Yet,
both showed a clear inverse γ-turn centered on the Imi residue
(Figure 2), and in particular for peptide 2b, having its Imi
residue at the position 2 of the sequence, the turn was
stabilized by an explicit H-bond with a H to O distance of 2.0
Å (Figures 2 and 3), consistent with the evidence of VT NMR
(Table S1 and Figure 1).
To simulate the dynamic behavior of the peptides, the
ROESY-derived conformers were analyzed by unrestrained
molecular dynamics in explicit water, for 10 ns at rt. During the
simulations, the γ-turn of 2b resulted to be remarkably stable,
correlated to the highly rigid Ala-Imi central scaﬀold and the
ﬂat imidazolidine-2-one ring. For 2d, having Imi at position 3,
the formation of a deﬁnite H-bond was prevented by a certain
conformational freedom of the short Phe-OMe portion, but
the γ-turn appearance was in general maintained. These results
were not unexpected; also peptides containing the homochiral
oxazolidin-2-one scaﬀold showed the preferential formation of
γ-turns in [D6]DMSO or other competitive solvents.
25
Figure 1. Sketches of 2b−e showing selected, meaningful proton−
proton NMR correlations indicated by arrows. The nonconventional
ImiCO···H−C(α-1) intramolecular interaction is rendered in
green, strong ROESY correlations are given in blue, medium-intensity
correlations are given in gray. The Δδ/Δt values for selected amide
protons are also shown as red ﬁgures.
Figure 2. Representative conformers of 2b−e calculated by ROESY-
restrained in a 30 × 30 × 30 Å3 box of standard TIP3P models of
equilibrated water. Heavy dotted lines represent H-bonds; light
dotted gray lines indicate distances; and ϕ/ψ dihedral angles of
selected residues are also reported in degrees.
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As for the heterochiral 2c and 2e, because of the many inter-
residue ROESY cross-peaks (Figure 1), the calculated
structures were tightly folded (2c and 2eA, Figure 2). The
sequence 2c, containing Imi at the position 2, presented a γ-
turn centered on Imi (Figure 2). Unexpectedly, the ROESY-
derived structure A of 2e (Figure 2) showed a regular γ-turn
centered on Imi, plus an atypical turn involving the residues
Ala-(R)-Imi-Phe, which seemed compatible with a ε-turn.35
The conformer 2eA was analyzed by unrestrained molecular
dynamics, and the analysis of the trajectories revealed the
formation of a 11-membered macrocycle closed by an
intramolecular H-bond between the Ala2NH and Phe4CO,
which is in agreement with the VT NMR temperature
coeﬃcient of AlaNH (Table S1). The representative structure
2eB shown in Figure 2 is characterized by a distance of 2.4 Å
between Ala2CO and Phe4NH and of 2.3 Å between
Ala2NH and Phe4CO (Figures 2 and 3).
The ε-turn is a rare kind of secondary structure which can be
observed in oligo-cyclopeptides and more seldom in linear
peptides and proteins composed of all α-amino acids.35 Unlike
the more common 5→1 13-membered α-, 4→1 10-membered
β-, and 3→1 7-membered γ-turns, the ε-turn involves 3
residues to form a hydrogen-bonded structure encompassing
11 atoms in the opposite 2→4 direction (Figure 3A). The ϕ/ψ
dihedral angles found in 2eB (Figure 2) assign the ε-turn to
the all-trans class A in the convention of Toniolo and
Balaram:35 (ϕ/ψ in degrees) Ala, −144/+68; (R)-Imi, +91/-
47; Phe, −133/+160.
The comparison between the structures of 2c and 2e in
Figure 2 showed that the ε-turn was not completely formed in
2c, albeit both compounds share the same Ala-(R)-Imi-Phe
tripeptide sequence. Possibly, the failure of 2c in forming an
unequivocal H-bonded 2→4 turn can be attributed to the
presence of the bulky Boc group at Ala1, as suggested by the
analysis of the trajectories of the unrestrained molecular
dynamics, which showed the clash between the tBu and Val4.
Finally, it is worth mentioning that in spite of the structural
similarity with (R)-Imi, the (R)-oxazolidin-2-one-4-carboxylate
scaﬀolds produced only “normal” conformations, that is, γ-
turns in [D6]DMSO and β-turns in CDCl3.
25a,b Also, oligomers
formed of repetitive Ala-(R)-oxazolidin-2-one-4-carboxylate
dipeptide units (≥5) folded in an ordered structure to give a
variant of the 310-helix, namely, a series of consecutive regular
4→1 β-turns (Figure 3B), in the crystal state and in MeOH.25c
At present, the exhaustive investigation of the structural
features of the Imi scaﬀold is beyond the scope of this work.
Nevertheless, some clues can be perceived by the inspection of
the X-ray crystal structures of 3-acyl-oxazolidin-2-one-4-
carboxylates25c and 3-acyl-imidazolidine-2-one-4-carboxy-
lates23 (Figure 3C,D). The comparison highlighted some
relevant 3D diﬀerences which might be responsible for the
diﬀerent H-bonding patterns. While the geometry of the ﬁve-
membered rings is quite twisted in the oxazolidin-2-one
(Figure 3C),25c it is extraordinarily ﬂat in the Imi ring (Figure
3D).23 This necessarily translates into diﬀerent orientations of
C4-carboxylate vectors, reasonably fundamental to the
development of the overall conformations, and in particular
Figure 3. Sketch of the expected inverse γ-turn of the homochiral 2b;
the ImiCO···H−C(α-1) interaction is rendered in green. Sketch of
the class A ε/γ-mixed turns35 in 2eB. (A) “Common way”
intramolecular hydrogen bonds in a tetrapeptide (residues numbered
1 to 4) rendered as continuous gray arrows and atypical 11-membered
ε-turn in the 2→4 reversed direction as a dotted arrow. (B)
Oligomers composed of Ala-oxazolidin-2-one units produce a helix of
“normal” β-turns.3c,25 (C) Crystal structure of the oxazolidin-2-one25c
and (D) of the imidazolidin-2-one scaﬀolds.23
Scheme 3. Synthesis of N1-Substituted Imi-Peptides 7
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the carboxylate group in the oxazolidin-2-one adopts an axial,
almost vertical orientation above the ﬁve-membered ring
(Figure 3C).
Imidazolidin-2-ones Substituted at the Position 1.
The formation of the Imi ring was attained by sacriﬁcing the
Nβ-amino group of Dap. Hence, Imi can be regarded as a
pseudo Pro showing the sole trans conformation at the
preceding peptide bond. Intriguingly, conformational analysis
by NMR and molecular dynamics has shown that (S)-Imi
peptides adopt an inverse γ-turn conformation, while (R)-Imi
promotes the formation of the rare ε/γ-secondary structure.
This unexpected observation prompted us to possibly expand
the scope of the Imi rings, making possible their use as general
promoters of such unusual secondary structures also in
sequences having at the position i residues other than a
(pseudo) Pro. For this reason, we tackled the opportunity to
introduce any substituents at the position 1 of the Imi
scaﬀolds.
The strategy we adopted is outlined in Scheme 3. Dipeptides
containing (S)- or (R)-serine 3 were prepared in solution as
described in the literature.36 The dipeptide esters 3 were
isolated in good yield (in the 70−85% range, 80−90% pure
according to analytical RP HPLC) by ﬂash chromatography
over silica gel. The dipeptides 3 were treated with a mixture of
triphenylphosphine, iodine (1.2 equiv each), and imidazole
(2.5 equiv),37 aﬀording β-iodo-Ala-dipeptides 4, not isolated
because of intrinsic instability;37 TLC analyses of the reaction
mixtures revealed the complete consumption of 3.
The displacement of iodine with alkyl or arylamines, that is,
methylamine, isopropylamine, aniline, allylamine, and γ-
aminobutyric acid (GABA) methyl ester (2.0 equiv) in
dimethylformamide (DMF) gave the Nβ-substituted Dap
dipeptides 5. Again, the TLC analyses of the crude reaction
mixtures showed the disappearance of the reagents. Unfortu-
nately, with the exception of Boc-Ala-Dap(N-allyl)-OMe 5d,
the isolation of these dipeptides 5 was not possible, either by
chromatography over silica gel or by preparative RP HPLC, for
the accumulation of the many side products.
Hence, we opted for the direct cyclization of the crude
dipeptides 5 with DSC/DIPEA, as reported above for the
synthesis of Imi-peptides 2. This reaction gave the formation of
the intermediate Nβ-carbamate 6, and of desired 7 only in
traces, as observed by RP HPLC and ESI MS analysis of the
reaction mixture. Even the highly pure 5d failed to give the
corresponding 7d, suggesting that the scarce purity of the other
reagents 5 was not the only responsible for the disappointing
result. Thereafter, the procedure was repeated upon varying
the conditions, using as the model reagent the crude dipeptide
Boc-Ala-Dap(N1Me)-OMe (5a), obtained from the Boc-Ala-β-
iodoAla-OMe 4a and methylamine. Besides DIPEA, also
Na2CO3, 4-dimethylaminopyridine (DMAP), and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) were tested. The
increase of the amounts of DSC and/or of the base and the
increase of temperature and of reaction time had very little
impact (not shown), while the use of DMF as the only solvent
gave a modest increase of the yield (Table 2, entry 1).
Apart from DSC, the use of other carbonates or dicarbonates
such as triphosgene, Boc2O, methyl chloroformate, CDI,
entries 2 to 5, respectively, in combination with DIPEA or the
other bases as above, was also poorly eﬀective. Gratifyingly, p-
nitrophenylchloroformate (pNPC)38 and DIPEA (1.5 equiv
each) in DMF at rt after 12 h gave 7a in 70% yield over 3 steps,
accompanied by the Nβ-p-nitrophenoxycarbonyl-Dap(Me)
intermediate 6 (25%) (entry 6). The yield was further
increased by replacing DIPEA with DBU, and 7a was isolated
in excellent amount (90%) by ﬂash chromatography over silica
gel (entry 7).
The same conditions were applied to the crude dipeptides
5b, c, e, obtained as reported in Scheme 3 from the
corresponding β-iodo-derivatives 4 and isopropylamine, ani-
line, allylamine, respectively. The N-terminal capping group,
the ester, and the amino acid preceding Dap, were varied to
check the generality of the process. The benzyl ester 5e was
preferred to the methyl ester 5d for the convenience of further
transformations, as discussed in the next sections. In all cases,
the reactions gave results comparable to 5a (entries 8 to 10).
Subsequently, the procedure was repeated starting from the
dipeptides containing D-serine. As for the (S)-conﬁgured series,
the formation of the dipeptides containing (R)-β-iodoAla,
followed by displacement with the same amines, gave the
dipeptides containing N-methyl, isopropyl, phenyl, and allyl
(R)-Dap. Then, the treatment with pNPC/DBU gave (R)-Imi
peptides 7f, 7g, 7h, and 7i in good to excellent yields (entries
11 to 14).
Finally, the dipeptide Boc-Ala-(S)-Imi[(CH2)3CO2Me]OBn
(7l) (Scheme 3) was prepared in suﬃcient yield by treatment
of the β-iodoAla-dipeptide with GABA methyl ester, followed
by cyclization under the usual conditions (entry 15).
Epimerization during the displacement of iodine from β-
iodoAla by the amines, or during the following cyclization step,
was excluded based on the comparison of the 1H NMR of the
(S,S)/(S,R) diastereomeric pairs with the peptides 2b−e
containing unsubstituted Imi. In particular, for all compounds
containing (R)-Imi in CDCl3, the proton ImiH4 appeared
≤4.75 ppm, while compounds containing (S)-Imi ImiH4
appeared ≥4.8 ppm.
In any case, to conﬁrm that the stereochemistry was
maintained, the diastereomeric 7a and 7f were treated with
LiOOH in THF/water at rt for 4 h, followed by 0.1 M HCl,39
leading to the detachment of Boc-Ala-OH and the release of
the enantiomeric methyl 1-methyl-2-oxoimidazolidine-4-car-
Table 2. Formation of Imi-Dipeptides 7 Using Carbonate/
Base (1.5 equiv) in DMF after 12 h at rt
entry compd carbonate/base 7 (%) purity (%)a 6 (%)
1 a DSC/DIPEA <10b − 70b
2 a (Cl3CO)CO/base
c traces d d
3 a Boc2O/base
c traces − 75
4 a ClCO2Me/base
c traces − 80
5 a CDI/basec <5b − traces
6 a pNPC/DIPEA 70b − 25
7 a pNPC/DBU 90e 95 traces
8 b pNPC/DBU 85e 91 traces
9 c pNPC/DBU 80e 92 10b
10 e pNPC/DBU 93e 94 traces
11 f pNPC/DBU 87e 93 traces
12 g pNPC/DBU 82e 91 traces
13 h pNPC/DBU 77e 96 11b
14 i pNPC/DBU 90e 92 traces
15 l pNPC/DBU 74e 94 traces
aAfter isolation, determined by RP HPLC ESI MS. bDetermined by
the RP HPLC analyses of the reaction mixtures. cBase: DIPEA,
carbonate, DMAP, DBU. dComplex mixture of byproducts.
eDetermined after isolation by ﬂash chromatography over 3 synthetic
steps respect to peptides 3.
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boxylates (S)-8 and (R)-8. After puriﬁcation by ﬂash
chromatography over silica gel (eluent cyclohexane/EtOAc
1:3), their speciﬁc optical rotation was determined (Scheme 4)
and judged in agreement with the literature for (S)-8: [α]D
20
+26.9 (c 1, MeOH).23
These Imi dipeptide scaﬀolds carrying three possible
diﬀerent pharmacophores can be of some interest in
peptidomimetic chemistry. There is evidence for the optimality
of three-residue motifs for biological activity.40 In a similar way
as shown for trans-pyrrolidine-3,4-dicarboxamide templates by
Boger et al. (Figure 4A),41 the triply functionalized Imi
dipeptides 7 (Figure 4) might be regarded as potential β-turn
mimetics when the turn amino acid i + 1 serves as a structural
rather than a recognition role, for example, Pro or Gly (Figure
4B). Hence, Imi scaﬀolds reproducing the side chains of the
residues i, i + 2, i + 3, could still maintain the bioactivity of the
native peptides.
As for the oligomers, the Imi scaﬀolds have been shown to
act as proline mimics inducing all-trans conformations in the
sequences, and to promote classic or unusual turn structures,
depending on the stereochemistry. Interestingly, while most of
the conformationally restricted turn-inducing elements (e.g.,
pseudoprolines, Freidinger lactams, spirolactams, bicyclic
thiazolidines, etc.) are generally deprived of some relevant
pharmacophores,1,42 the Imi rings can be equipped with
proteogenic side chains (Figure 4C), for example, of Ala, Val,
Phe (Scheme 3).
To further challenge the potential utility of the N1-
substituted Imi dipeptides, Boc-Ala-(R)-Imi(N1allyl)-OBn
(7i) was subjected to catalytic hydrogenation, and the resulting
(R)-Imi(N1propyl) dipeptide acid was coupled with H-Phe-
OMe·HCl, giving the tripeptide 9 equipped with a non-
proteogenic side chain (Scheme 5). As expected, the 1H NMR
analysis of 9 in 8:2 [D6]DMSO/H2O supported the fact that
this Imi-N1-propyl tripeptide adopted a conformation con-
sistent to that of the heterochiral models 2c or 2e. Indeed, the
1H NMR of 9 was practically superimposable to that of the
Boc-Ala-(R)-Imi-Phe portion of 2c, while the only diﬀerence
with the corresponding portion in 2d was the obviously
diﬀerent chemical shift of AlaNH (Supporting Information).
See for instance the highly reproducible pattern of the
resonances of H4 and the two H5 protons (Supporting
Information).
On the other hand, the synthetic strategy described above
was utilized also for introducing substituents carrying
orthogonally protected functional groups. A ﬁrst example was
the dipeptide Boc-Ala-(S)-Imi[(CH2)3CO2Me]OBn (7l)
(Table 2, entry 15, and Figure 4), prepared with GABA
methyl ester. In perspective, after hydrolysis under basic
conditions, the N1-butanoic acid side chain might be exploited
to graft the peptide onto, for example, surfaces, polymeric
materials, nanoparticles, and so forth.
Finally, the N1-substituent of Imi can be equipped with a tag
residue for site-selective modiﬁcations of the sequences.
Among the most popular reactions utilized to transform such
handles without perturbing the remaining amino acids, it is
possible to cite the Cu-catalyzed azide−alkyne cycloaddition,
the Sonogashira, Suzuki−Miyaura, Mizoroki−Heck, Diels−
Alder reactions, the photo-1,3-dipolar cycloaddition, the
Staudinger ligation, and the oleﬁn metathesis with Grubbs or
Hoveyda−Grubbs catalysts.17
As a proof of concept, the allyl substituent at the position 1
of the Imi ring in 7e was selectively derivatized with N-Boc-4-
bromoaniline by the Heck reaction (Scheme 6). Conducted in
DMF in the presence of Pd(OAc)2/PPh3/TEA, under an inert
atmosphere, at 80 °C,43 the reaction gave the adduct 10
characterized by a exclusively trans connection between the
two portions, as determined by the −CHCH− coupling
constants in the 1H NMR, J = 15.6 Hz (for trans alkenes J =
12−18 Hz, for cis alkenes J = 6−12 Hz). The reduction by
catalytic hydrogenation gave a fully ﬂexible linkage, and at the
same time removed the benzyl ester protection, giving the
Scheme 4. Cleavage of the Imi Rings 8 from 7a, f
Figure 4. (A) Pyrrolidine- and Imi-based β-turn mimetics 7.41 (B)
Classic γ- or β-turns. (C) Imi as a turn-inducing element for
peptidomimetics equipped with side chains at each residue. Triply
substituted Imi peptide 7l with orthogonally protected, further
functionalizable groups.
Scheme 5. Synthesis of the N1-Substituted Imi-Tripeptide 9
from the N1-Allyl Imi-Tripeptide 7i
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dipeptide acid 11, ready in prospective for the extension of the
peptidic backbone.
■ CONCLUSIONS
The introduction of nitrogen heterocycles into peptide
sequences represents an eﬀective approach to increase
enzymatic stability and to induce well-deﬁned secondary
structures. To this purpose, we developed an expedient
synthesis of hybrid peptides containing Imi scaﬀolds. These
exceptionally ﬂat pseudo-prolines demonstrated the ability to
favor unusual conformations in a competitive and biomimetic
solvent. While (S)-Imi peptides adopted a γ-turn conforma-
tion, (R)-conﬁgured Imi promoted the additional formation of
a ε-turn, an infrequent secondary structure characterized by a
11-membered 2→4 H-bond going opposite respect to the
classic γ- or β-turns. Besides, Imi can be equipped at the
position N1 with substituents that reproduce the side chains of
native amino acids, including Ala, Val, or Phe, in either L- or D-
conﬁguration, as well as with non-proteinogenic substituents,
such as n-propyl or allyl. In this respect, the N1-substituted
(R)-Imi rings represent a new class of general promoters the
rare ε-turn in a variety of peptide sequences. On the other
hand, Imi can also carry functional groups, for instance, the
allyl group, capable of selective reactions without perturbing
the rest of the structure, for example by the Heck reaction.
Potential future applications might include the glycosylation,
prenylation, PEGylation, biotinylation, or attachment to solid
surfaces, self-assembled monolayers, proteins, or the con-
jugation with ﬂuorophores or antibodies.17,44
■ EXPERIMENTAL SECTION
General Experimental Methods. All purchased reagents were
used without further puriﬁcations. Purities were assessed by analytical
RP HPLC and conﬁrmed by exact mass and elemental analysis. MW
lab station: MicroSYNTH equipped with a built-in ATC-FO
advanced ﬁber optic automatic temperature control. RP HPLC:
Agilent 1100 series apparatus, with a RP column Phenomenex mod.
Gemini 3μ C18 110 Å 100 × 3.0 mm, stationary phase octadecyl
carbon chain-bonded silica with trimethylsilyl endcapping, fully
porous organo-silica solid support, particle size 3 μm, pore size 110
Å, length 100 mm, internal diameter 3 mm, DAD 210 and 254 nm,
mobile phase from 9:1 to 2:8 water/CH3CN, in 20 min, at a ﬂow rate
of 0.5 mL min−1, followed by 10 min at the same composition.
Semipreparative RP-HPLC: Agilent 1100 series, RP column
ZORBAX mod. Eclipse XDBC18 PrepHT cartridge 21.2 × 150 mm
7 μm, stationary phase octadecyl carbon chain bonded silica, double
endcapped, particle size 7 mm, pore size 80 Å, length 150 mm,
internal diameter 21.2 mm, DAD 210 nm; mobile phase from H2O/
CH3CN (8:2) to CH3CN (100%) in 10 min at a ﬂow rate of 12 mL
min−1. HRMS: Waters Xevo QTof. Routine ESI MS: MS single
quadrupole HP 1100MSD detector, drying gas ﬂow of 12.5 L min−1,
nebulizer pressure 30 psgi, drying gas temp 350 °C, capillary voltage
4500(1) and 4000(2), scan 50−2600 amu. Elemental analysis:
Thermo Flash 2000CHNS/O. NMR characterization was done on a
Varian Gemini 400 or 200, using 0.01−0.04 M peptide in 5 mm tubes
at rt, using the solvents CDCl3, or [D6]DMSO, or 8:2 [D6]DMSO/
H2O (water suppression by the solvent presaturation procedure
PRESAT); 1H spectra were recorded at 400 MHz, and the
unambiguous assignment of the resonances was done by 2D
gCOSY; proton-decoupled 13C NMR was recorded at 100 or 75
MHz; chemical shifts were reported as δ values in ppm relative to
solvent as internal standard.
Synthesis of Peptides 1 in Solution. The general procedure is
as follows: A mixture of the Boc-amino acid (0.3 mmol) and HOBt
(0.049 g, 0.36 mmol) was stirred in 3:1 DCM/DMF (5 mL) at rt, and
after 10 min, the amino ester counterpart (0.36 mmol), EDC·HCl
(0.069 g, 0.36 mmol), and TEA (0.13 mL, 0.94 mmol) were added in
sequence while stirring at rt. After 2 h, the solvents were removed at
reduced pressure, and the residue was diluted with ethyl acetate
(EtOAc; 20 mL). The slurry mixture was washed with 0.1 M HCl (5
mL) and a saturated solution of NaHCO3 (5 mL). The organic layer
was dried over Na2SO4 and the solvent was evaporated at reduced
pressure. The intermediate crude peptides, obtained in quantitative
yield, were analyzed by RP HPLC and ESI MS and were used without
further puriﬁcations.
Boc deprotection was accomplished by stirring the crude peptides
in 1:3 TFA/DCM (4 mL) for 30 min. Then, the mixture was
concentrated at reduced pressure, and the treatment was repeated.
The residue was suspended in Et2O (20 mL), and the peptide−TFA
salts which precipitated in almost quantitative yield were used for the
next couplings without further puriﬁcations.
The ﬁnal sequences 1 were isolated by ﬂash chromatography over
silica gel (eluent 1:2 cyclohexane/EtOAc), 80−85% yield, 80−90%
pure by RP HPLC (general methods). The identity was conﬁrmed by
ESI MS analysis (general methods).
Cyclization to Imi-Peptides 2a−c in Solution. The general
procedure is as follows: The peptides 1 (0.2 mmol) were dissolved in
EtOH (15 mL), and a 2 L balloon ﬁlled with H2 was applied in the
presence of a catalytic amount of 10% Pd/C, while stirring at rt. The
reactions were monitored by TLC and were generally judged
complete in 6 h. Then, the mixture was ﬁltered over Celite and the
solvent was evaporated at reduced pressure.
The residue was dissolved in 3:1 DCM/DMF (5 mL), and DSC
(0.061 g, 0.24 mmol) and DIPEA (0.044 mL, 0.24 mmol) were added
at rt under inert atmosphere. The mixture was stirred for 3 h, then the
solvent was distilled under reduced pressure, the residue was diluted
with 0.1 M HCl (5 mL), and the mixture was extracted three times
with DCM (10 mL). The combined organic layers were dried over
Na2SO4 and concentrated at reduced pressure. The residue was
separated by semipreparative RP HPLC on a C18 column, eluent
from H2O/CH3CN (8:2) to CH3CN (100%) in 10 min, at a ﬂow rate
of 12 mL min−1 (general methods), and purity was determined by RP
HPLC (general methods).
Boc-Ala-(S)-Imi-Phe-OMe (2a). Cyclization of 1a (0.11 g, 0.19
mmol) according to the general procedure gave 2a (0.077 g, 86%,
92% pure). 1H NMR (8:2 [D6]DMSO/H2O, 400 MHz): δ 1.17 (d, J
= 7.1 Hz, 3H, AlaMe), 1.35 (s, 9H, tBu), 2.93−3.02 (m, 2H, PheHβ),
3.08 (dd, J = 3.0, 9.6 Hz, 1H, ImiH5), 3.57 (s, 3H, OMe), 3.63 (dd, J
= 9.6, 10.0 Hz, 1H, ImiH5), 4.44 (m, 1H, PheHα), 4.75 (dd, J = 3.0,
10.0 Hz, 1H, ImiH4), 5.18 (dd, J = 7.1, 14.4 Hz, 1H, AlaHα), 7.09 (d,
J = 8.0 Hz, 1H, AlaNH), 7.18−7.35 (m, 5H, ArH), 7.73 (s, 1H,
ImiNH1), 8.58 (d, J = 6.8 Hz, 1H, PheNH); 13C{1H} NMR
([D6]DMSO, 100 MHz): δ 18.2, 29.1, 37.5, 41.3, 49.0, 52.8, 54.7,
Scheme 6. Heck Reaction of the N1-Allyl Imi-Tripeptide 7e, Giving 10 and Then 11
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55.3, 78.8, 127.6, 129.3, 130.0, 137.7, 156.1, 170.6, 172.7, 174.4;
HRMS (ESI/QTOF) m/z: [M + H]+ calcd for C22H31N4O7,
463.2193; found, 463.2164. Anal. Calcd for C22H30N4O7: C, 57.13;
H, 6.54; N, 12.11. Found: C, 57.19; H, 6.49; N, 11.99.
Boc-Ala-(S)-Imi-Phe-Val-OMe (2b). Cyclization of 1b (0.14 g, 0.21
mmol) according to the general procedure gave 2b (0.10 g, 88%, 93%
pure). 1H NMR (8:2 [D6]DMSO/H2O, 400 MHz): δ 0.82−0.93 (m,
6H, ValMe), 1.17 (d, J = 7.2 Hz, 3H, AlaMe), 1.34 (s, 9H, tBu), 2.01
(m, 1H, ValHβ), 2.80 (dd, J = 8.8, 13.4 Hz, 1H, PheHβ), 2.99 (dd, J
= 4.0, 13.4 Hz, 1H, PheHβ), 3.08 (dd, J = 2.2, 9.8 Hz, 1H, ImiH5),
3.58 (m, 1H, ImiH5), 3.62 (s, 3H, OMe), 4.14 (dd, J = 7.2, 7.6 Hz,
1H, ValHα), 4.56 (m, 1H, PheHα), 4.73 (dd, J = 2.8, 7.2 Hz, 1H,
ImiH4), 5.16 (m, 1H, AlaHα), 7.00 (d, J = 7.6 Hz, 1H, AlaNH),
7.16−7.30 (m, 5H, PheArH), 7.71 (s, 1H, ImiNH1), 8.24 (d, J = 7.6
Hz, 1H, ValNH), 8.28 (d, J = 8.0 Hz, 1H, PheNH); 13C{1H} NMR
(CDCl3, 100 MHz): δ 17.8, 18.8, 28.3, 29.7, 31.1, 38.1, 49.0, 52.2,
54.9, 56.0, 57.5, 79.9, 127.1, 127.2, 128.8, 129.1, 129.3, 136.0, 154.6,
155.2, 168.5, 170.2, 171.6, 175.0; HRMS (ESI/QTOF) m/z: [M +
H]+ calcd for C27H40N5O8, 562.2877; found, 562.2821. Anal. Calcd
for C27H39N5O8: C, 57.74; H, 7.00; N, 12.47. Found: C, 57.81; H,
6.90; N, 12.54.
Boc-Ala-(R)-Imi-Phe-Val-OMe (2c). Cyclization of 1c (0.12 g, 0.18
mmol) according to the general procedure gave 2c (0.092 g, 91%,
93% pure). 1H NMR (8:2 [D6]DMSO/H2O, 400 MHz): δ 0.88 (d, J
= 7.2 Hz, 3H, ValMe), 0.91 (d, J = 6.8 Hz, 3H, ValMe), 1.15 (d, J =
6.4 Hz, 3H, AlaMe), 1.35 (s, 9H, tBu), 2.05 (m, 1H, ValHβ), 2.42 (m,
1H, ImiH5), 2.71 (dd, J = 10.0, 13.7 Hz, 1H, PheHβ), 3.06 (dd, J =
3.8, 13.7 Hz, 1H, PheHβ), 3.34 (dd, J = 4.8, 12.0 Hz, 1H, ImiH5),
3.63 (s, 3H, OMe), 4.30 (m, 1H, ValHα), 4.56 (m, 1H, ImiH4), 4.71
(ddd, J = 3.8, 8.8, 10.0 Hz, 1H, PheHα), 5.31 (dq, J = 6.4, 8.8 Hz, 1H,
AlaHα), 6.62 (d, J = 8.8 Hz, 1H, AlaNH), 7.17−7.27 (m, 5H,
PheArH), 7.62 (s, 1H, ImiNH1), 8.20 (d, J = 7.6 Hz, 1H, ValNH),
8.37 (d, J = 8.8 Hz, 1H, PheNH); 13C{1H} NMR ([D6]DMSO, 100
MHz): δ 18.5, 19.0, 19.2, 28.3, 29.9, 30.8, 38.0, 48.1, 51.8, 53.0, 55.2,
57.8, 78.1, 126.4, 128.0, 129.4, 137.6, 154.6, 155.0, 169.2, 171.3,
171.8, 172.9; HRMS (ESI/QTOF) m/z: [M + H]+ calcd for
C27H40N5O8, 562.2877; found, 562.2849. Anal. Calcd for
C27H39N5O8: C, 57.74; H, 7.00; N, 12.47. Found: C, 57.55; H,
7.13; N, 12.17.
Synthesis of Imi-Peptides 2d, e in Solid-Phase. The general
procedure is as follows: Wang resin pre-loaded with Fmoc-Phe (0.25
g, 0.4−0.8 mmol g−1, particle size 100−200 mesh) was placed into a
reactor equipped with a ﬁlter and suspended in DCM (5 mL). Fmoc
was removed by treatment with 1:4 piperidine/DMF (5 mL) under
MW irradiation at 40 W while bubbling N2 in an open vessel,
monitoring the internal temperature at 45 °C. After 2 min, the
suspension was ﬁltered, and the procedure was repeated. Then, the
resin was washed three times in sequence with DCM, DMF, and
MeOH (5 mL each).
The resin was swollen in DCM (8 mL), and a mixture of Fmoc-
Dap(Cbz)OH (0.137 g, 0.3 mmol) and HOBt (0.041 g, 0.3 mmol) in
DMF (4 mL) was added, followed by DCC (0.078 g, 0.38 mmol).
The mixture was heated at 45 °C for 10 min under MW irradiation as
described above, while bubbling N2. The resin was ﬁltered and
washed three times with the sequence DCM, DMF, MeOH (5 mL
each). Coupling eﬃcacy was determined by means of the Kaiser test.
All the remaining residues were attached by the same protocols.
The resulting peptidyl-resin 1d or 1e was suspended in 1:3 iPrOH/
toluene (10 mL), and HCO2NH4 (0.038 g, 0.6 mmol) and a catalytic
amount of 10% Pd/C were added in sequence. The mixture was
irradiated at 600 W for eight cycles of 1 min each. The resin-bound
peptide was ﬁltered and washed three times in sequence with DCM,
DMF, and MeOH (5 mL each).
Then, the peptidyl-resin was suspended in 3:1 DCM/DMF (5
mL), and DSC (0.116 g, 0.45 mmol) and DIPEA (80 μL, 0.45 mmol)
were added at rt under inert atmosphere. After 3 h, the mixture was
ﬁltered, and the resin-bound peptide was washed three times in
sequence with DCM, DMF, and MeOH (5 mL each).
A suspension of the peptidyl-resin in 1:3 TEA/MeOH (20 mL)
was heated at 60 °C for 20 min under MW irradiation in an open
vessel. After ﬁltration, the resin was washed twice with DCM and
Et2O (10 mL each), the ﬁltrates were collected, and the volatiles were
evaporated at reduced pressure. The Imi-peptides were separated by
semipreparative RP HPLC on a C18 column (general methods)
giving 2d or 2e in good yield (calculated on an average resin load of
0.6 mmol g−1), and high purity, as determined by analytical RP HPLC
(general methods).
Boc-Val-Ala-(S)-Imi-Phe-OMe (2d). The procedure gave peptide
2d (0.069 g, 84%, 95% pure). 1H NMR (8:2 [D6]DMSO/H2O, 400
MHz): δ 0.85 (d, J = 6.8 Hz, 3H, ValMe), 0.87 (d, J = 6.8 Hz, 3H,
ValMe), 1.24 (d, J = 7.0 Hz, 3H, AlaMe), 1.38 (s, 9H, tBu), 1.93 (m,
1H, ValHβ), 2.97 (dd, J = 7.6, 13.8 Hz, 1H, PheHβ), 3.02 (dd, J =
5.6, 13.8 Hz, 1H, PheHβ), 3.09 (dd, J = 3.4, 9.4 Hz, 1H, ImiH5), 3.57
(s, 3H, OMe), 3.62 (m, 1H, ImiH5), 3.79 (m, 1H, ValHα), 4.44
(ddd, J = 5.6, 6.8, 7.6 Hz, 1H, PheHα), 4.75 (dd, J = 3.4, 10.0 Hz, 1H,
ImiH4), 5.45 (m, 1H, AlaHα), 6.59 (d, J = 9.2 Hz, 1H, ValNH),
7.19−7.24 (m, 3H, PheArH), 7.25−7.31 (m, 2H, PheArH), 7.77 (s,
1H, ImiNH1), 8.00 (d, J = 7.6 Hz, 1H, AlaNH), 8.59 (d, J = 6.8 Hz,
1H, PheNH); 13C{1H} NMR ([D6]DMSO, 75 MHz): δ 18.5, 19.1,
20.1, 29.1, 29.9, 30.4, 31.5, 37.4, 52.8, 54.7, 55.3, 60.1, 79.9, 127.6,
129.2, 130.0, 137.7, 156.0, 156.7170.5, 171.7, 172.6, 174.4; HRMS
(ESI/QTOF) m/z: [M + H]+ calcd for C27H40N5O8, 562.2877;
found, 562.2822. Anal. Calcd for C27H39N5O8: C, 57.74; H, 7.00; N,
12.47. Found: C, 57.85; H, 6.85; N, 12.58.
Boc-Val-Ala-(R)-Imi-Phe-OMe (2e). The procedure gave peptide
2e (0.071 g, 86%, 96% pure). 1H NMR (8:2 [D6]DMSO/H2O, 400
MHz): δ 0.76 (d, J = 6.8 Hz, 3H, ValMe), 0.81 (d, J = 6.0 Hz, 3H,
ValMe), 1.20 (d, J = 6.4 Hz, 3H, AlaMe), 1.35 (s, 9H, tBu), 1.94 (m,
1H, ValHβ), 2.67 (dd, J = 2.2, 9.8 Hz, 1H, ImiH5), 2.88 (dd, J = 10.0,
13.3 Hz, 1H, PheHβ), 3.06 (dd, J = 5.4, 13.3 Hz, 1H, PheHβ), 3.45
(m, 1H, ImiH5), 3.61 (s, 3H, OMe), 3.80 (dd, J = 6.6, 8.0 Hz, 1H,
ValHα), 4.48 (ddd, J = 5.4, 8.0, 10.0 Hz, 1H, PheHα), 4.60 (dd, J =
2.2, 9.8 Hz, 1H, ImiH4), 5.58 (m, 1H, AlaHα), 6.75 (d, J = 8.0 Hz,
1H, ValNH), 7.16−7.22 (m, 3H, PheArH), 7.23−7.30 (m, 2H,
PheArH), 7.73 (s, 1H, ImiNH1), 7.86 (d, J = 8.0 Hz, 1H, AlaNH),
8.54 (d, J = 8.0 Hz, 1H, PheNH); 13C{1H} NMR ([D6]DMSO, 100
MHz): δ 18.9, 19.2, 19.6, 28.6, 30.7, 37.4, 41.0, 47.1, 52.3, 53.7, 55.4,
56.5, 60.0, 78.6, 124.8, 126.0, 127.0, 128.6, 129.6, 137.4, 155.2, 155.9,
169.6, 171.0, 172.0, 172.7; HRMS (ESI/QTOF) m/z: [M + H]+
calcd for C27H40N5O8, 562.2877; found, 562.2845. Anal. Calcd for
C27H39N5O8: C, 57.74; H, 7.00; N, 12.47. Found: C, 57.90, H, 6.83,
N, 12.60.
Conformational Analysis by NMR. Peptide samples were
dissolved in 8:2 [D6]DMSO/H2O in 5 mm tubes to the ﬁnal
concentration of 0.01 M. At this concentration, the intramolecular
aggregation in mixtures of [D6]DMSO and H2O is usually
unimportant. Besides, self-association of the peptides was excluded
based on the reproducibility of the chemical shift of non-exchangeable
protons in the concentration range 0.01−0.04 M (not shown). Water
suppression was achieved by the PRESAT procedure implemented in
Varian. Proton resonance assignment was accomplished through
gCOSY. VT 1H NMR experiments were recorded over the range of
298−348 K; temperature calibration was done with the ethylene
glycol OHCHn chemical shift separation method. 2D ROESY
experiments were done at rt, phase-sensitive mode, spin-locking
ﬁeld (γb2) = 2000 Hz, mixing time = 250 ms; spectra were processed
in the hypercomplex approach; peaks were calibrated on solvent. Only
ROESY-derived constraints were included in the restrained molecular
dynamics (MD). Cross-peak intensities were ranked and associated to
the distances (Å): very strong = 2.3, strong = 2.6, medium = 3.0, weak
= 5.0. The intensities of the cross peaks arising from protons
separated by known distances (e.g., geminal) were found to match
with these associations, but were discarded. For the absence of Hα(i, i
+ 1) ROESY cross peaks, all of the ω bonds were set at 180° ( f
constant: 16 kcal mol−1 Å−2).
MD Simulations. The restrained MD simulations were conducted
at 300 K and 1 atm by using the AMBER force ﬁeld in a 30 × 30 × 30
Å3 box of standard TIP3P models of equilibrated water, periodic
boundary conditions dielectric scale factor = 1, and cutoﬀ for the
nonbonded interactions = 12 Å; all water molecules closer than 2.3 Å
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to a solute atom were eliminated, and 50 random structures were
generated by a 100 ps simulation at 1200 K; these were subsequently
subjected to restrained MD, 50 ps with a 50% scaled force ﬁeld at
1200 K, then by 50 ps with full distance restraints, force constant = 7
kcal mol−1 Å−2, after which the system was cooled in 20 ps to 50 K.
H-bond interactions were not included, nor were torsion angle
restraints. The resulting structures were minimized by 3000 cycles of
steepest descent and 3000 cycles of conjugated gradient, and
convergence = 0.01 kcal Å−1 mol−1. The backbones of the structures
were clustered by the rmsd analysis.
Unrestrained MD simulations were performed starting with the
conformation derived from ROESY in the box of standard TIP3P
water for 10 ns at 298 K using periodic boundary conditions, at
constant temperature and pressure (Berendsen scheme,45 bath
relaxation constant of 0.2). For 1−4 scale factors, van der Waals
and electrostatic interactions are scaled in AMBER to half their
nominal value. The integration time step was set to 0.1 fs. The system
coordinates were collected every picosecond.
Synthesis of Peptides 3. The reaction was performed under
conditions which allow using (S)- or (R)-serine esters without
protection of the hydroxy group.36 Brieﬂy, a stirred solution of the N-
protected amino acid (0.5 mmol) in 4:1 DCM/DMF (4 mL) was
treated with HOBt (0.6 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexaﬂuorophosphate (HBTU, 0.6 mmol) at rt
and under inert atmosphere. After 5 min, serine ester (0.55 mmol)
and DIPEA (1.2 mmol) were added, and the reaction was stirred for
10 min under MW irradiation, setting the internal reaction
temperature at 80 °C. After concentration of the mixture at reduced
pressure, the residue was diluted with EtOAc (20 mL). The organic
layer was washed with 0.1 M HCl (5 mL), and a saturated solution of
NaHCO3 (5 mL) was dried over Na2SO4. After evaporation of the
solvent at reduced pressure, the crude dipeptide esters 3 were isolated
(70−85%, 80−90% pure according to analytical RP HPLC) by ﬂash
chromatography over silica gel (eluent 1:3 cyclohexane/EtOAc) and
were identiﬁed by ESI MS.
Synthesis of N1-Substituted Imi-Peptides 7. The general
procedure is as follows: To a solution of triphenylphosphine (0.080 g,
0.31 mmol) in anhydrous DCM (4 mL), iodine (0.080 g, 0.32 mmol)
was added at rt under inert atmosphere and magnetic stirring. After 15
min, imidazole (0.043 g, 0.6 mmol) was also added and the mixture
was stirred for additional 15 min. The dipeptide 3 (0.25 mmol),
dissolved in DCM (2 mL), was ﬁnally added and the reaction mixture
reﬂuxed for 2 h. The mixture was then cooled, diluted with DCM (6
mL), and washed with 10% Na2S2O4 in water (4 mL). The organic
layer was dried over Na2SO4, and the solvents were evaporated at
reduced pressure to the ﬁnal volume of 3 mL. The solution was
allowed to stand at 5 °C overnight, and some white solid Ph3PO
which precipitated not quantitatively was removed by ﬁltration and
washed with DCM (5 mL). The ﬁltrate was evaporated at reduced
pressure to give the crude iodides 4.
The crude iodides 4 (0.25 mmol) were dissolved in anhydrous
DMF (5 mL), the amine (0.5 mmol) was added, and the mixture was
heated at 50 °C for 3 h. Then, DMF was distilled at reduced pressure,
the residue was suspended in 0.1 M HCl (12 mL), and the mixture
was washed with Et2O (5 mL). The pH of the water layer was
corrected to 9−10 with sat. Na2CO3, and then it was extracted 3 times
with EtOAc (5 mL). The collected organic layers were dried over
Na2SO4, and solvent was removed at reduced pressure. The crude
residues were utilized for the next step without further puriﬁcations,
the only exception being 5d, which was puriﬁed as described
thereafter.
Boc-Ala-Dap(Allyl)-OMe (5d). The residue was puriﬁed by ﬂash
chromatography over silica gel (eluent EtOAc/MeOH 98:2), giving
the dipeptide (0.058 g, 70%, 94% pure by RP HPLC). 1H NMR
(CDCl3, 400 MHz): 2 conformers δ 1.39 (d, J = 6.8 Hz, 3H, AlaMe),
1.44 + 1.45 (s, 9H, tBu), 1.69 (br s, 1H, NH), 2.98 (dd, J = 4.4, 12.7
Hz, 1H, DapHβ), 3.08 (dd, J = 5.4, 12.7 Hz, 1H, DapHβ), 3.22−3.27
(m, 2H, NCH2), 3.76 (s, 3H, OMe), 4.19 (m, 1H, AlaHα), 4.63 (m,
1H, DapHα), 4.99 (br d, 1H, AlaNH), 5.05−5.19 (m, 2H, CH2),
5.82 (m, 1H, CH), 6.92 + 7.06 (br d, 1H, DapNH); 13C{1H} NMR
(CDCl3, 100 MHz): 2 conformers δ 18.7, 28.6, 49.8, 52.3, 52.6, 52.8,
55.2, 77.6, 116.7 + 116.8, 136.5 + 136.6, 155.7, 172.0 + 172.1, 172.9 +
173.0; HRMS (ESI/QTOF) m/z: [M + H]+ calcd for C15H28N3O5,
330.2029; found, 330.2060. Anal. Calcd for C15H27N3O5: C, 54.70; H,
8.26; N, 12.76. Found: C, 54.84; H, 8.33; N, 12.87.
The oily residues containing the crude dipeptides 5 were dissolved
in DMF (5 mL), pNPC (0.075 g, 0.38 mmol) and DBU (0.055 g,
0.38 mmol) were added, and the mixture was stirred at rt for 12 h.
The solvent was distilled at reduced pressure, and 0.1 M HCl (4 mL)
was added, and then the residue was extracted 3 times with EtOAc (5
mL). The collected organic layers were dried over Na2SO4, and the
solvent was removed at reduced pressure. The Imi dipeptides 7 were
isolated from the resulting mixtures by ﬂash chromatography over
silica gel (eluent EtOAc/MeOH 98:2), and purity was determined by
RP HPLC (general methods).
Boc-Ala-(S)-Imi(N1Me)-OMe (7a). Starting from 3a (0.070 g, 0.24
mmol), the general procedure gave 7a (0.071 g, 90%, 95% pure). 1H
NMR (CDCl3, 400 MHz): δ 1.38−1.48 (m, 12H, AlaMe + tBu), 2.87
(s, 3H, NMe), 3.38 (dd, J = 3.4, 9.8 Hz, 1H, ImiH5), 3.71 (t, J = 10.0
Hz, 1H, ImiH5), 3.77 (s, 3H, OMe), 4.82 (dd, J = 3.4, 9.8 Hz, 1H,
ImiH4), 5.08 (d, J = 7.6 Hz, 1H, AlaNH), 5.51 (m, 1H, AlaHα);
13C{1H} NMR (CDCl3, 100 MHz): δ 18.4, 28.3, 30.5, 46.6, 48.7,
51.9, 52.9, 79.6, 153.1, 155.3, 169.9, 174.1; HRMS (ESI/QTOF) m/
z: [M + H]+ calcd for C14H24N3O6, 330.1665; found, 330.1688. Anal.
Calcd for C14H23N3O6: C, 51.06; H, 7.04; N, 12.76. Found: C, 50.84;
H, 7.28; N, 13.00.
Cbz-Val-(S)-Imi(N1iPr)-OMe (7b). Starting from 3b (0.088 g, 0.25
mmol), the general procedure gave 7b (0.089 g, 85%, 91% pure). 1H
NMR (CDCl3, 400 MHz): δ 0.86 (d, J = 7.2 Hz, 3H, ValMe), 0.95 (d,
J = 7.2 Hz, 3H, ValMe), 1.02 (d, J = 6.4 Hz, 3H, iPrMe), 1.10 (d, J =
6.4 Hz, 3H, iPrMe), 2.25 (m, 1H, ValHβ), 2.35 (m, 1H, N1CH), 3.33
(dd, J = 3.6, 9.8 Hz, 1H, ImiH5), 3.66 (t, J = 9.8 Hz, 1H, ImiH5),
3.78 (s, 3H, OMe), 4.82 (dd, J = 3.6, 9.8 Hz, 1H, ImiH4), 5.11 (br s,
2H, PhCH2), 5.41 (d, J = 8.0 Hz, 1H, ValNH), 5.61 (m, 1H, ValHα),
7.33−7.41 (m, 5H, ArH); 13C{1H} NMR (CDCl3, 100 MHz): δ 16.6,
18.8, 21.1, 22.6, 28.7, 41.4, 48.3, 50.2, 52.5, 56.7, 61.2, 128.0, 129.0,
129.1, 137.7, 153.4, 155.9, 173.5, 175.3; HRMS (ESI/QTOF) m/z:
[M + H]+ calcd for C21H30N3O6, 420.2135; found, 420.2172. Anal.
Calcd for C21H29N3O6: C, 60.13; H, 6.97. N, 10.02. Found: C, 60.22;
H, 7.26; N, 10.10.
Boc-Ala-(S)-Imi(N1Ph)-OBn (7c). Starting from 3c (0.084 g, 0.23
mmol), the general procedure gave 7c (0.072 g, 80%, 92% pure). 1H
NMR (CDCl3, 400 MHz): δ 1.40 (d, J = 6.8 Hz, 3H, AlaMe), 1.44 (s,
9H, tBu), 3.84 (dd, J = 3.2, 9.6 Hz, 1H, ImiH5), 4.19 (dd, J = 9.6,
10.0 Hz, 1H, ImiH5), 5.00 (dd, J = 3.2, 10.0 Hz, 1H, ImiH4), 5.10 (d,
J = 7.2, 1H, AlaNH), 5.17 (d, J = 12.0 Hz, 1H, PhCH), 5.26 (d, J =
12.0 Hz, 1H, PhCH), 5.53 (m, 1H, AlaHα), 7.18 (m, 1H, ArH),
7.30−7.41 (m, 7H, ArH), 7.43−7.50 (m, 2H, ArH); 13C{1H} NMR
(CDCl3, 100 MHz): δ 18.2, 28.3, 45.3, 49.1, 51.6, 67.9, 79.8, 119.3,
124.9, 128.5, 128.7, 128.8, 129.1, 134.6, 137.9, 150.9, 155.3, 168.9,
174.4; HRMS (ESI/QTOF) m/z: [M + H]+ calcd for C19H26N3O6,
392.1822; found, 392.1856. Anal. Calcd for C19H25N3O6: C, 58.30; H,
6.44; N, 10.74. Found: C, 58.47; H, 6.35; N, 10.83.
Boc-Ala-(S)-Imi(N1Allyl)-OBn (7e). Starting from 3c
46 (0.091 g,
0.25 mmol), the general procedure gave 7e (0.099 g, 93%, 94% pure).
1H NMR (CDCl3, 400 MHz): δ 1.36 (d, J = 7.2 Hz, 3H, AlaMe), 1.43
(s, 9H, tBu), 3.32 (dd, J = 3.0, 9.8 Hz, 1H, ImiH5), 3.65 (dd, J = 9.8,
10.4 Hz, 1H, ImiH5), 3.78 (dd, J = 5.2, 14.8 Hz, 1H, CH2−CH),
3.92 (dd, J = 6.2, 15.8 Hz, 1H, CH2−CH), 4.87 (dd, J = 3.0, 10.4
Hz, 1H, ImiH4), 5.08 (d, J = 8.0 Hz, 1H, AlaNH), 5.17−5.27 (m, 4H,
CH2 + PhCH2), 5.49 (m, 1H, AlaHα), 5.65 (m, 1H, −CH),
7.30−7.40 (m, 5H, ArH); 13C{1H} NMR, (CDCl3, 100 MHz): δ
18.7, 28.6, 44.5, 46.5, 49.2, 52.5, 68.1, 80.1, 119.5, 126.5, 128.8, 129.0,
131.5, 135.1, 153.1, 155.7, 169.6, 174.5; HRMS (ESI/QTOF) m/z:
[M + H]+ calcd for C22H30N3O6, 432.2135; found, 432.2166. Anal.
Calcd for C22H29N3O6: C, 61.24; H, 6.77; N, 9.74. Found: C, 61.38;
H, 6.84; N, 9.81.
Boc-(S)-Ala-(R)-Imi(N1Me)-OMe (7f). Starting from 3f (0.073 g,
0.25 mmol), the general procedure gave 7f (0.072 g, 87%, 93% pure).
1H NMR (CDCl3, 400 MHz): δ 1.36 (d, J = 7.2, 1H, AlaMe), 1.42 (s,
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9H, tBu), 2.88 (s, 3H, NMe), 3.38 (dd, J = 3.4, 9.7 Hz, 1H, ImiH5),
3.71 (dd, J = 9.7, 10.4 Hz, 1H, ImiH5), 3.76 (s, 3H, OMe), 4.70 (dd,
J = 3.4, 10.4 Hz, 1H, ImiH4), 5.36 (br d, 1H, AlaNH), 5.51 (m, 1H,
AlaHα); 13C{1H} NMR (CDCl3, 100 MHz): δ 19.3, 28.2, 30.5, 46.6,
51.8, 52.4, 52.8, 79.3, 153.1, 154.8, 169.7, 173.9; HRMS (ESI/
QTOF) m/z: [M + H]+ calcd for C14H24N3O6, 330.1665; found,
330.1692. Anal. Calcd for C14H23N3O6: C, 51.06; H, 7.04; N, 12.76.
Found: C, 50.76; H, 7.39; N, 13.04.
Cbz-Val-(R)-Imi(N1iPr)-OMe (7g). Starting from 3g (0.084 g, 0.24
mmol), the general procedure gave 7g (0.082 g, 82%, 91% pure). 1H
NMR (CDCl3, 400 MHz): δ 0.83 (d, J = 7.2 Hz, 3H, ValMe), 0.86 (d,
J = 7.2 Hz, 3H, ValMe), 1.05 (d, J = 6.4 Hz, 3H, iPrMe), 1.10 (d, J =
6.4 Hz, 3H, iPrMe), 2.19 (m, 1H, ValHβ), 2.37 (m, 1H, N1CH), 3.32
(dd, J = 3.6, 9.8 Hz, 1H, ImiH5), 3.66 (t, J = 9.8 Hz, 1H, ImiH5),
3.78 (s, 3H, OMe), 4.69 (dd, J = 3.6, 9.8 Hz, 1H, ImiH4), 5.08−5.15
(m, 2H, PhCH2), 5.57−5.62 (m, 2H, ValHα+ValNH), 7.28−7.39 (m,
5H, ArH); 13C{1H} NMR (CDCl3, 100 MHz): δ 16.3, 17.4, 20.3,
28.8, 40.5, 52.2, 53.4, 55.0, 59.2, 67.0, 127.9, 128.7, 129.1, 129.5,
137.1, 152.5, 155.0, 172.3, 174.5; HRMS (ESI/QTOF) m/z: [M +
H]+ calcd for C21H30N3O6, 420.2135; found, 420.2166. Anal. Calcd
for C21H29N3O6: C, 60.13; H, 6.97; N, 10.02. Found: C, 60.30; H,
7.20; N, 10.19.
Boc-Ala-(R)-Imi(N1Ph)-OBn (7h). Starting from 3h (0.091 g, 0.25
mmol), the general procedure gave 7h (0.074 g, 77%, 96% pure). 1H
NMR (CDCl3, 400 MHz): δ 1.44 (d, J = 6.4 Hz, 3H, AlaMe), 1.47 (s,
9H, tBu), 3.77 (dd, J = 2.6, 10.2 Hz, 1H, ImiH5), 4.23 (dd, J = 9.8,
10.2 Hz, 1H, ImiH5), 4.88 (dd, J = 2.6, 9.8 Hz, 1H, ImiH4), 5.23 (s,
2H, PhCH2), 5.44 (br d, 1H, AlaNH), 5.65 (m, 1H, AlaHα), 7.19 (m,
1H, ArH), 7.30−7.41 (m, 7H, ArH), 7.43−7.51 (m, 2H, ArH);
13C{1H} NMR (CDCl3, 100 MHz): δ 19.5, 28.4, 45.3, 49.5, 52.1,
67.9, 79.6, 119.2, 125.0, 126.1, 128.3, 128.7, 129.2, 134.8, 137.8,
150.8, 154.8, 168.7, 174.2; HRMS (ESI/QTOF) m/z: [M + H]+
calcd for C19H26N3O6, 392.1822; found, 392.1861. Anal. Calcd for
C19H25N3O6: C, 58.30; H, 6.44; N, 10.74. Found: C, 58.44; H, 6.51;
N, 10.90.
Boc-Ala-(R)-Imi(N1Allyl)-OBn (7i). Starting from 3h
46 (0.088 g,
0.24 mmol), the general procedure gave 7i (0.093 g, 90%, 92% pure).
1H NMR (CDCl3, 400 MHz): δ 1.40 (d, J = 6.8 Hz, 3H, AlaMe), 1.46
(s, 9H, tBu), 3.29 (dd, J = 3.4, 9.8 Hz, 1H, ImiH5), 3.64 (dd, J = 9.8,
10.4 Hz, 1H, ImiH5), 3.77 (dd, J = 5.8, 15.6 Hz, 1H, CH2−CH),
3.96 (dd, J = 5.4, 15.6 Hz, 1H, CH2−CH), 4.74 (dd, J = 3.4, 10.4
Hz, 1H, ImiH4), 5.15−5.22 (m, 4H, PhCH2 + CH2), 5.40 (br d,
1H, AlaNH), 5.56 (m, 1H, AlaHα), 5.66 (m, 1H,CH2), 7.30−7.39
(m, 5H, Ar); 13C{1H} NMR (CDCl3, 100 MHz): δ 19.9, 28.7, 44.4,
46.5, 49.5, 53.1, 68.0, 79.9, 119.4, 128.8, 128.9, 120.0, 131.5, 135.3,
152.9, 155.1, 169.4, 174.3; HRMS (ESI/QTOF) m/z: [M + H]+
calcd for C22H30N3O6, 432.2135; found, 432.2167. Anal. Calcd for
C22H29N3O6: C, 61.24; H, 6.77; N, 9.74. Found: C, 61.33; H, 6.68; N,
9.66.
Boc-Ala-(S)-Imi[N1(CH2)3CO2Me]-OBn (7l). Starting from 3c
46
(0.081 g, 0.22 mmol), the general procedure gave 7l (0.080 g, 74%,
94% pure). 1H NMR (CDCl3, 400 MHz): δ 1.35 (d, J = 6.4Hz, 3H,
AlaMe), 1.43 (s, 9H, tBu), 1.78−1.86 (m, 2H, CH2), 2.30−2.38 (m,
2H, CH2), 3.24 (m, 1H, CH2), 3.35−3.40 (m, 2H, CH2 + ImiH5),
3.63−3.77 (m, 4H, COOMe + ImiH5), 4.87 (dd, J = 3.4, 10.2, 1H,
ImiH4), 5.07 (d, J = 8.4 Hz, 1H, AlaNH), 5.15 (d, J = 12.2 Hz, 1H,
PhCH), 5.25 (d, J = 12.2 Hz, 1H, PhCH), 5.46 (m, 1H, AlaHα),
7.25−7.38 (m, 5H, ArH); 13C{1H} NMR (CDCl3, 100 MHz): δ 14.6,
22.6, 28.7, 31.3, 43.4, 44.9, 48.0, 52.5, 68.2, 80.0, 128.8, 129.1, 143.1,
153.4, 155.9, 173.5, 175.3; HRMS (ESI/QTOF) m/z: [M + H]+
calcd for C24H34N3O8, 492.2346; found, 492.2329. Anal. Calcd for
C24H33N3O8: C, 58.64; H, 6.77; N, 8.55. Found: C, 58.78; H, 6.82; N,
8.60.
(S)- or (R)-Methyl-1-methyl-2-oxoimidazolidine-4-carboxylates
(S)-8 or (R)-8. To a stirred suspension of LiOH (0.028 g, 1.2 mmol)
in tetrahydrofuran (THF; 6 mL) and water (1.5 mL), a solution of
H2O2 (30 wt %, 0.28 mL, 2.3 mmol) was added at 0 °C. After 15 min,
a solution of 7a or 7f (0.13 g, 0.4 mmol) in THF (3 mL) was added at
0 °C while stirring. The temperature was allowed to rise to rt, and
after 4 h, the pH was adjusted to 5−6 with 0.1 M HCl, THF was
evaporated at reduced pressure, and the mixture was extracted three
times with EtOAc. The collected organic layers were dried over
Na2SO4, and the residue was puriﬁed by ﬂash chromatography over
silica gel (eluent cyclohexane/EtOAc 1:3) giving (S)-8 (0.050 g, 0.32
mmol, 80% yield, 94% pure) or (R)-8 (0.047 g, 0.30 mmol, 75% yield,
94% pure), and their [α]D speciﬁc optical rotations were determined
to be +25 (c 0.7, MeOH) and −24 (c 0.6, MeOH), respectively; liter-
ature for (S)-8: [α]D
20 +26.9 (c 1, MeOH).23
Boc-Ala-(R)-Imi(N1nPr)-Phe-OMe (9). The dipeptide 7i (0.1 g, 0.23
mmol) was subjected to hydrogenation in the presence of a catalytic
amount of 10% Pd/C in EtOH (10 mL) at rt. The reaction was
monitored by TLC, and after 6 h, the solution was ﬁltered over Celite.
The solvent was removed at reduced pressure, and the presence of the
dipeptide acid was conﬁrmed by RP HPLC and ESI MS.
The residue was dissolved in 3:1 DCM/DMF (6 mL) and reacted
with HOBt (0.038 g, 0.28 mmol), H-Phe-OMe·HCl (0.060 g, 0.28
mmol), EDC·HCl (0.054 g, 0.28 mmol), and TEA (0.083 mL, 0.60
mmol). The reaction was conducted as described for peptides 1, and
after the usual work up, the Imi-tripeptide 9 was isolated as described
for the Imi-peptides 2 (0.090 g, 78%, 88% pure according to analytical
RP HPLC, general methods). 1H NMR (8:2 [D6]DMSO/H2O, 400
MHz): δ 0.74 (t, J = 7.3 Hz, 3H, Me), 1.16 (d, J = 6.4 Hz, 3H,
AlaMe), 1.27−1.34 (m, 2H, CH2), 1.36 (s, 9H, tBu), 2.56 (dd, J =
3.0, 9.5 Hz, 1H, ImiH5), 2.85 (dd, J = 10.8, 13.2 Hz, PheHβ), 2.95
(m, 1H, NCH2), 3.07−3.17 (m, 2H, PheHβ + NCH2), 3.46 (dd, J =
9.5, 10.0 Hz, 1H, ImiH5), 3.65 (s, 3H, OMe), 4.50−4.60 (m, 2H,
PheHα + ImiH4), 5.34 (m, 1H, AlaHα), 6.76 (d, J = 8.8 Hz, 1H,
AlaNH), 7.17−7.22 (m, 3H, PheArH), 7.22−7.30 (m, 2H, PheArH),
8.59 (d, J = 8.0 Hz, 1H, PheNH); 13C{1H} NMR ([D6]DMSO, 100
MHz): δ 11.7, 19.9, 20.5, 29.1, 38.1, 45.0, 45.7, 49.0, 53.0, 53.5,
HRMS (ESI/QTOF) m/z: [M + H]+ calcd for C25H37N4O7,
505.2662; found, 505.2685. Anal. Calcd for C25H36N4O7: C, 59.51;
H, 7.19; N, 11.10. Found: C, 59.71; H, 7.22; N, 11.05.
Boc-Ala-(S)-Imi((E)-3-(4-((tert-butoxycarbonyl)amino)phenyl)-
allyl)-OBn (10). A mixture of dipeptide 7e (0.056 g, 0.13 mmol), N-
Boc-4-bromoaniline (0.054 g, 0.2 mmol), palladium acetate (0.3 mg,
0.0013 mmol), and triphenylphosphine (0.7 mg, 0.0026 mmol) were
stirred in 1:2 TEA/DMF (3 mL) under inert atmosphere. The
mixture was stirred for 18 h at 80 °C. Then, the mixture was
evaporated at reduced pressure, MeOH (15 mL) was added to the
residue, and the suspension was ﬁltered through a Celite pad to
remove the ﬁne black Pd0. The solvent was evaporated at reduced
pressure, and the residue was dissolved in EtOAc (20 mL) and
washed with 1 M HCl (4 mL). The organic layer was dried over
Na2SO4, and after evaporation at reduced pressure, the residue was
puriﬁed by semipreparative RP HPLC over a C18 column (general
methods), giving 10 (0.063 g, 0.10 mmol, 78%, 92% pure by analytical
RP HPLC, general methods). 1H NMR (CDCl3, 400 MHz): δ 1.26
(s, 9H, tBu), 1.38 (d, J = 6.8 Hz, 3H, AlaMe), 1.44 (s, 9H, tBu), 3.35
(dd, J = 3.4, 9.9 Hz, 1H, ImiH5), 3.70 (dd, J = 9.9, 10.3 Hz, 1H,
ImiH5), 3.97 (dd, J = 6.4, 15.4 Hz, 1H, CH−CH), 4.07 (dd, J =
6.6, 15.4 Hz, 1H, CH−CH), 4.88 (dd, J = 3.4, 10.3 Hz, 1H,
ImiH4), 5.07 (d, J = 7.6 Hz, 1H, AlaNH), 5.13 (d, J = 12.2 Hz, 1H,
CHPh), 5.23 (d, J = 12.2 Hz, 1H, CHPh), 5.51 (m, 1H, AlaHα), 6.06
(m, 1H, CH), 6.54 (d, J = 15.6 Hz, 1H, CH), 7.28−7.36 (m, 7H,
ArH), 7.39 (d, J = 8.8 Hz, 2H, ArH); 13C{1H} NMR (CDCl3, 100
MHz): δ 17.2, 28.7 × 2, 43.6, 48.5, 50.8, 53.1, 66.3, 81.7, 120.4, 124.0,
126.9, 129.0, 130.1, 132.2, 135.0, 137.8, 151.8, 152.8, 155.0, 172.1,
175.5; HRMS (ESI/QTOF) m/z: [M + H]+ calcd for C33H43N4O8,
623.3081; found, 623.3101. Anal. Calcd for C33H42N4O8: C, 63.65; H,
6.80; N, 9.00. Found: C, 61.41; H, 6.68; N, 9.05.
Boc-Ala-(S)-Imi(3-(4-((tert-butoxycarbonyl)amino)phenyl)-
propyl)-OBn (11). The dipeptide 10 (0.063 g, 0.10 mmol) was treated
with H2 in the presence of a catalytic amount of 10% Pd/C in EtOH
at rt. The reaction was monitored by TLC, and after 8 h, the solution
was ﬁltered over Celite, and the solvent was removed at reduced
pressure, giving dipeptide acid 11 (0.053 g, 99%, 85% pure by
analytical RP HPLC, general methods). 1H NMR (CDCl3, 400
MHz): δ 1.12−1.23 (m, 12H, tBu + AlaMe), 1.31, (s, 9H, tBu), 1.57−
1.64 (m, 2H, CH2), 2.37−2.42 (m, 2H, CH2), 2.93−3.17 (m, 2H,
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CH2), 3.27 (m, 1H, ImiH5), 3.41 (m, 1H, ImiH5), 4.28 (m, 1H,
ImiH4), 5.27 (m, 1H, AlaHα), 5.66 (br d, 1H, AlaNH), 6.96 (d, J =
8.0 Hz, 2H, ArH), 7.22 (d, J = 8.0 Hz, 2H, ArH), 10.50 (br s, 1H,
COOH); 13C{1H} NMR (CDCl3, 100 MHz): δ 17.5, 25.7, 27.1, 28.9,
31.7, 40.9, 48.0, 50.0, 55.8, 80.4, 81.0, 119.9, 121.1, 126.3, 127.6,
134.1, 135.3, 152.0, 153.0, 155.1, 171.9, 174.3; HRMS (ESI/QTOF)
m/z: [M + H]+ calcd for C26H39N4O8, 535.2768; found, 535.2804.
Anal. Calcd for C26H38N4O8: C, 58.41; H, 7.16; N, 10.48. Found: C,
58.66; H, 7.30; N, 10.20.
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Ramakrishnan, C.; Kalmankar, N.; Balaram, P. Intramolecular
backbone···backbone hydrogen bonds in polypeptide conformations.
The other way around: ε-turn. Biopolymers 2017, 108, No. e22911.
(36) De Marco, R.; Cavina, L.; Greco, A.; Gentilucci, L. Easy
preparation of dehydroalanine building blocks equipped with
oxazolidin-2-one chiral auxiliaries, and applications to the stereo-
selective synthesis of substituted tryptophans. Amino Acids 2014, 46,
2823−2839.
(37) Caputo, R.; Longobardo, L. Enantiopure β3-amino acids-2,2-d2
via homologation of proteinogenic α-amino acids. Biopolymers 2007,
32, 401−404.
(38) Blanco-Canosa, J. B.; Dawson, P. E. An Efficient Fmoc-SPPS
Approach for the Generation of Thioester Peptide Precursors for Use
in Native Chemical Ligation. Angew. Chem., Int. Ed. 2008, 120, 6957−
6961.
(39) (a) Cardillo, G.; Gentilucci, L.; De Matteis, V. Lewis acid-
promoted synthesis and reactivity of β-O-benzylhydroxylamino imides
derived from D-glyceraldehyde. J. Org. Chem. 2002, 67, 5957−5962.
(b) Gage, J. R.; Evans, D. A. Diastereoselective aldol condensation
using a chiral oxazolidinone auxiliary: (2S*,3S*)-3-hydroxy-3-phenyl-
2-methylpropanoic acid. Org. Synth. 1990, 68, 83−91.
(40) Ung, P.; Winkler, D. A. Tripeptide motifs in biology: targets for
peptidomimetic design. J. Med. Chem. 2011, 54, 1111−1125.
(41) Whitby, L. R.; Ando, Y.; Setola, V.; Vogt, P. K.; Roth, B. L.;
Boger, D. L. Design, synthesis, and validation of a β-turn mimetic
library targeting protein-protein and peptide-receptor interactions. J.
Am. Chem. Soc. 2011, 133, 10184−10194.
(42) (a) Souers, A. J.; Ellman, J. A. β-Turn mimetic library synthesis:
scaffolds and applications. Tetrahedron 2001, 57, 7431−7448.
(b) MacDonald, M.; Aube, J. Approaches to cyclic peptide beta
turn mimics. Curr. Org. Chem. 2001, 5, 417−438. (c) Hirschmann, R.
F.; Nicolaou, K. C.; Angeles, A. R.; Chen, J. S.; Smith, A. B., III The β-
D-glucose scaffold as a β-turn mimetic. Acc. Chem. Res. 2009, 42,
1511−1520.
(43) Malek, N. J.; Moormann, A. E. Palladium-catalyzed synthesis of
cinnamylamines. J. Org. Chem. 1982, 47, 5395−5397.
(44) (a) Wilson, P. Synthesis and applications of protein/peptide-
polymer conjugates. Macromol. Chem. Phys. 2017, 218, 1600595−
1600609. (b) Zong, J.; Cobb, S. L.; Cameron, N. R. Peptide-
functionalized gold nanoparticles: versatile biomaterials for diagnostic
and therapeutic applications. Biomater. Sci. 2017, 5, 872−886.
(c) Arosio, D.; Manzoni, L.; Corno, C.; Perego, P. Integrin-targeted
peptide- and peptidomimetic-drug conjugates for the treatment of
tumors. Recent Pat. Anti-Cancer Drug Discovery 2017, 12, 148−168.
(d) Wang, L.; Zhang, Y.; Wu, A.; Wei, G. Designed graphene-peptide
nanocomposites for biosensor applications: A review. Anal. Chim. Acta
2017, 985, 24−40. (e) Narayanaswamy, R.; Wang, T.; Torchilin, V. P.
Improving peptide applications using nanotechnology. Curr. Top.
Med. Chem. 2016, 16, 253−270. (f) Szweda, R.; Szweda, D.;
Kosowski, D.; Dworak, A.; Trzebicka, B. Polymer-peptide/protein
conjugates on the surface. Curr. Org. Chem. 2017, 21, 1579−1599.
(g) Greco, A.; Maggini, L.; De Cola, L.; De Marco, R.; Gentilucci, L.
Diagnostic implementation of fast and selective integrin-mediated
adhesion of cancer cells on functionalized zeolite L monolayers.
Bioconjugate Chem. 2015, 26, 1873−1878. (h) De Marco, R.; Greco,
A.; Calonghi, N.; Dattoli, S. D.; Baiula, M.; Spampinato, S.; Picchetti,
P.; De Cola, L.; Anselmi, M.; Cipriani, F.; Gentilucci, L. Selective
detection of α4β1 integrin (VLA-4)-expressing cells using peptide-
functionalized nanostructured materials mimicking endothelial
surfaces adjacent to inflammatory sites. Peptide Science 2018, 110,
No. e23081.
(45) Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.;
DiNola, A.; Haak, J. R. Molecular dynamics with coupling to an
external bath. J. Chem. Phys. 1984, 81, 3684−3690.
(46) 3c = 3e = 3l; 3h = 3i.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.8b03055
J. Org. Chem. 2019, 84, 4992−5004
5004
